Research Topics
| Frank VocciSummaryAffiliation: National Institutes of Health Country: USA Publications
| Collaborators
|
Detail Information
Publications
Assessment of neurotoxicity from potential medications for drug abuse: ibogaine testing and brain imagingF J Vocci
Medications Development Division, National Institute on Drug Abuse, Rockville, Maryland 20857, USA
Ann N Y Acad Sci 820:29-39; discussion 39-40. 1997..This "harbinger of toxicity" approach would provide clinicians the critical data necessary for appropriate follow-up of subjects as well as the propriety of continuance of the clinical trials within the ibogaine project...- Vaccines against nicotine: how effective are they likely to be in preventing smoking?F J Vocci
Division of Treatment Research and Development, National Institute on Drug Abuse, Bethesda, Maryland, USA
CNS Drugs 15:505-14. 2001..The rationale behind the approach is that nicotine is the pharmacological agent controlling the rate of cigarette smoking, and reducing its rate and extent of uptake into the brain may have therapeutic benefits... - Medications development: successes and challengesFrank Vocci
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA
Pharmacol Ther 108:94-108. 2005..Initial studies are underway. Both agonist and antagonist approaches will be evaluated. Additionally, medications will be tested in cannabis-dependent patients for the management of insomnia, withdrawal, and concurrent depression... - Medication development for addictive disorders: the state of the scienceFrank J Vocci
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, 6001 Executive Blvd, Rm 4133, MSC 9551, Bethesda, MD 20892 9551, USA
Am J Psychiatry 162:1432-40. 2005..Potential medications that modulate these mechanisms are highlighted... 
Modafinil for the treatment of cocaine dependenceAnn L Anderson
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Bethesda, MD 20892 9551, USA
Drug Alcohol Depend 104:133-9. 2009..Modafinil was tested for efficacy in facilitating abstinence in cocaine-dependent patients, compared to placebo...- Pharmacotherapy of methamphetamine addiction: an updateAhmed Elkashef
Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Subst Abus 29:31-49. 2008..Preclinical data suggest that use of GVG, CB1 antagonist, and lobeline are also promising therapeutic strategies... - Bupropion for the treatment of methamphetamine dependenceAhmed M Elkashef
Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences, National Institutes of Health, National Institute on Drug Abuse, Bethesda, MD, USA
Neuropsychopharmacology 33:1162-70. 2008.... - Novel medications to treat addictive disordersIvan D Montoya
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Room 4143, Bethesda, MD 20892 9551, USA
Curr Psychiatry Rep 10:392-8. 2008..This article reviews the current medications that are medically safe and have shown promising results for treating opioid, cocaine, methamphetamine, and cannabis addictions... - Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependenceDeborah B Leiderman
Center for Drug Evaluation and Research, Food and Drug Administration, Rockville, MD 20852, USA
Addiction 100:1-11. 2005.... - Biotechnology and the treatment of addictive disorders: new opportunitiesAhmed Elkashef
Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMC, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, Maryland 20892 9551, USA
BioDrugs 21:259-67. 2007..The main focus of this review is on the development of immunotherapy for stimulants and nicotine addiction as a model highlighting the current status of the science and potential emerging discoveries and development... 
Clinical management of drug addicts infected with human immunodeficiency virus and hepatitis C virusJag H Khalsa
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, NIH, 6001 Executive Boulevard, Bethesda, MD 20892, USA
J Addict Dis 27:1-10. 2008..Clinical management of substance abusers with infections is possible, available, and effective if individuals in drug treatment programs are closely monitored for adherence and compliance to HIV/HCV treatment regimens...- Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependenceAhmed Elkashef
Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD, USA
Addiction 100:91-101. 2005..0% of females while 17.9% of males achieved this criterion. CONCLUSIONS: Results presented here may prove useful for planning future clinical trials for therapies targeting cocaine dependence... - Prevalence of abnormal liver-associated enzymes in cocaine experienced adults versus healthy volunteers during phase 1 clinical trialsLouis R Cantilena
Division of Clinical Pharmacology and Medical Toxicology, Uniformed Services University of the Health Sciences, Bethesda, MD 20814 4799, USA
Contemp Clin Trials 28:695-704. 2007..The potential to obscure important signals for hepatotoxicity during Phase 1 research may be higher in the CE study population... - Double-blind, placebo-controlled trial of selegiline transdermal system (STS) for the treatment of cocaine dependenceAhmed Elkashef
National Institute on Drug Abuse NIDA, Division of Pharmacotherapies and Medical Consequences of Drug Abuse DPMCDA, MSC 9551 Bethesda, MD 20892, USA
Drug Alcohol Depend 85:191-7. 2006..The contrast of this result to earlier, promising preclinical and human pilot data could be due to factors associated with sample size, patient characteristics, dose, or poor predictive validity of preclinical models... - Biological markers of cocaine addiction: implications for medications developmentAhmed Elkashef
Division of Treatment, Research and Development DTR and D, National Institute on Drug Abuse NIDA, National Institutes of Health NIH, Bethesda, MD 20892, USA
Addict Biol 8:123-39. 2003..Merging the biology within medications studies of cocaine abusers could prove useful for targeting specific pharmacological agents to subgroups of patients, prediction of response to medication and relapse to use... - The NIDA Methamphetamine Clinical Trials Group: a strategy to increase clinical trials research capacityAhmed Elkashef
Division of Treatment Research and Development, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Addiction 102:107-13. 2007..This multi-site infrastructure would serve to run multiple Phases II and III protocols effectively and expeditiously... - Marijuana neurobiology and treatmentAhmed Elkashef
Clinical Medical Branch, Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Bethesda, MD 20892, USA
Subst Abus 29:17-29. 2008..The next few years looking promising for translational research efforts to make treatment widely accessible to patients with marijuana dependence... - Intravenous cocaine and QT variabilityMark C P Haigney
Division of Cardiology, Department of Medicine, Uniformed Services University of the Health Sciences, Bethesda, MD 20814, USA
J Cardiovasc Electrophysiol 17:610-6. 2006..Dynamic instability in cardiac repolarization may contribute to drug-induced arrhythmogenesis. We hypothesized that intravenous cocaine would significantly destabilize repolarization as measured by QT variability... - The challenging interactions between antiretroviral agents and addiction drugsJag Khalsa
Center on AIDS and Other Medical Consequences of Drug Abuse (CAMCODA, National Institute on Drug Abuse, NIH, Rockville, MD, USA
Am Clin Lab 21:10-3. 2002 - The SRPHK1 outcome measure for cocaine-dependence trials combines self-report, urine benzoylecgonine levels, and the concordance between the two to determine a cocaine-use status for each study dayEugene Somoza
Department of Psychiatry, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
Drug Alcohol Depend 93:132-40. 2008.... - 6-[18F]Fluoro-A-85380, a new PET tracer for the nicotinic acetylcholine receptor: studies in the human brain and in vivo demonstration of specific binding in white matterYu-Shin Ding
Chemistry Department, Brookhaven National Laboratory, Upton, New York 11973, USA
Synapse 53:184-9. 2004 - Cocaine Rapid Efficacy Screening Trials (CREST): lessons learnedKyle M Kampman
Philadelphia Veterans Affairs Medical Center, Philadelphia, PA, USA
Addiction 100:102-10. 2005....